The Era of COVID-19 and the Rise of Science Collectivism in Cancer Research.
Journal
Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
pubmed:
15
5
2020
medline:
21
7
2020
entrez:
15
5
2020
Statut:
ppublish
Résumé
The coronavirus SARS-CoV-2 has created a global pandemic that has killed more than a quarter million people since December 2019, halted commerce, and disrupted our ability to research cancer in the laboratory and clinic and care for our patients. A return to a functioning society can be facilitated by the active participation of cancer researchers to diagnose and treat SARS-CoV-2-infected patients, and the direct and indirect benefits of our involvement cannot be overstated.
Identifiants
pubmed: 32404307
pii: 2159-8290.CD-20-0657
doi: 10.1158/2159-8290.CD-20-0657
doi:
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
913-915Subventions
Organisme : NCI NIH HHS
ID : P30 CA045508
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020;323:1406–7.
Ladha A, Joung J, Abudayyeh O, Gootenberg J, Zhang F. A 5-min RNA preparation method for COVID-19 detection with RT-qPCR. MedRxiv. 2020.
Broughton JP, Deng X, Yu G, Fasching CL, Servellita V, Singh J, et al. CRISPR–Cas12-based detection of SARS-CoV-2. Nat Biotechnol. 2020 Apr 16.
Kellner MJ, Koob JG, Gootenberg JS, Abudayyeh OO, Zhang F. SHERLOCK: nucleic acid detection with CRISPR nucleases. Nat Protoc. 2019;14:2986–3012.
Rabe BA, Cepko C. SARS-CoV-2 detection using an isothermal amplification reaction and a rapid, inexpensive protocol for sample inactivation and purification. MedRxiv. 2020.
Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444–8.
Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368:473–4.
Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020 Apr 29.
Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020 May 7.
Treon SP, Castillo J, Skarbnik AP, Soumerai JD, Ghobrial IM, Guerrera ML, et al. The BTK-inhibitor ibrutinib may protect against pulmonary injury in COVID-19 infected patients. Blood. 2020 Apr 17.
Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, et al. Targeting potential drivers of COVID-19: neutrophil extracellular traps. J Exp Med. 2020;217:pii:e20200652.
Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020 Apr 30.
Ziegler C, Allon SJ, Nyquist SK, Mbano I, Miao VN, Cao Y, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is enriched in specific cell subsets across tissues. Cell. 2020 Mar 17.
Lamers MM, Beumer J, van der Vaart J, Knoops K, Puschhof J, Breugem T, et al. SARS-CoV-2 productively infects human gut enterocytes. Science. 2020 May 1.